There are 2867 resources available
1091P - Predictive and prognostic value of Patras Immunotherapy Score (PIOS) in patients with advanced NSCLC treated with immunotherapy/chemotherapy combination
Presenter: Fotinos-Ioannis Dimitrakopoulos
Session: Poster session 15
1503P - Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French sarcoma group
Presenter: Armelle Dufresne
Session: Poster session 11
820P - Nivolumab (NIVO) +/- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naïve or -refractory basal cell carcinoma (BCC)
Presenter: Kara Schenk
Session: Poster session 03
1092P - Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC)
Presenter: Fortunato Ciardiello
Session: Poster session 15
1504P - Real-world treatment patterns and outcomes of metastatic synovial sarcoma over the last decade in England
Presenter: Sandra Strauss
Session: Poster session 11
821P - Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
Presenter: Max Schlaak
Session: Poster session 03
1093P - RET rearrangements detection by FISH in lung cancer, literature review and comparison with results from a French centre
Presenter: Anne Mc Leer
Session: Poster session 15
1505P - Risk factors for metastatic disease at presentation with synovial sarcoma
Presenter: Yu Kong
Session: Poster session 11
822P - Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM)
Presenter: Noha Abdel-Wahab
Session: Poster session 03
1094P - The clinical potential of circulating-free DNA (cfDNA) for real-time longitudinally monitoring clinical outcomes in a real-world first-line non-small cell lung cancer (NSCLC) prospective study
Presenter: Valerio Gristina
Session: Poster session 15